Carcinoma of the colon in ulcerative colitis

Goldgraber, Moshe B.; Kirsner, Joseph B.

doi:10.1002/1097-0142(196405)17:5<657::aid-cncr2820170515>3.0.co;2-7

Cited by 110 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 76 208 209 It is also the first meta-analysis of stratified (by duration of disease) cancer incidence rates. The precision of the pooled estimates, both overall and stratified, is due to the relatively large numbers of observations, but the pooled estimates also take into account the between study heterogeneity, as they are based on random effects meta-analysis models.…”

Section: Discussionmentioning

confidence: 99%

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

Eaden

Abrams

Mayberry

2001

Gut

2,559

1,706

View full text Add to dashboard Cite

Background and aims-Controversy surrounds the risk of colorectal cancer (CRC) in ulcerative colitis (UC). Many studies have investigated this risk and reported widely varying rates. Methods-A literature search using Medline with the explosion of references identified 194 studies. Of these, 116 met our inclusion criteria from which the number of patients and cancers detected could be extracted. Overall pooled estimates, with 95% confidence intervals (CI), of cancer prevalence and incidence were obtained using a random eVects model on either the log odds or log incidence scale, as appropriate. Results-The overall prevalence of CRC in any UC patient, based on 116 studies, was estimated to be 3.7% (95% CI 3.2-4.2%). Of the 116 studies, 41 reported colitis duration. From these the overall incidence rate was 3/1000 person years duration (pyd), (95% CI 2/1000 to 4/1000). The overall incidence rate for any child was 6/1000 pyd (95% CI 3/1000 to 13/1000). Of the 41 studies, 19 reported results stratified into 10 year intervals of disease duration. For the first 10 years the incidence rate was 2/1000 pyd (95% CI 1/1000 to 2/1000), for the second decade the incidence rate was estimated to be 7/1000 pyd (95% CI 4/1000 to 12/1000), and in the third decade the incidence rate was 12/1000 pyd (95% CI 7/1000 to 19/1000). These incidence rates corresponded to cumulative probabilities of 2% by 10 years, 8% by 20 years, and 18% by 30 years. The worldwide cancer incidence rates varied geographically, being 5/1000 pyd in the USA, 4/1000 pyd in the UK, and 2/1000 pyd in Scandinavia and other countries. Over time the cancer risk has increased since 1955 but this finding was not significant (p=0.8). Conclusions-Using new meta-analysis techniques we determined the risk of CRC in UC by decade of disease and defined the risk in pancolitics and children. We found a non-significant increase in risk over time and estimated how risk varies with geography. (Gut 2001;48:526-535)

show abstract

Section: Discussionmentioning

confidence: 99%

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

Eaden

Abrams

Mayberry

2001

Gut

2,559

1,706

View full text Add to dashboard Cite

show abstract

“…People with chronic inflammation of the large bowel as seen in ulcerative colitis have a greater likelihood of developing colon cancer [1,2]. People who use aspirin/ NSAIDs, a possible indicator of lower levels of inflammation, have consistently been shown to have reduced risk of CRC [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

IL6 genotypes and colon and rectal cancer

Slattery

Wolff

Herrick

et al. 2007

Cancer Causes Control

View full text Add to dashboard Cite

Inflammation appears to play a key role in the development of colorectal cancer (CRC). In this study we examine factors involved in the regulation of inflammation and risk of CRC. Data from a multicenter case-control study of colon (N = 1579 cases and N = 1977 controls) and rectal (N = 794 cases and N = 1005 controls) cancer were used to evaluate the association between the rs1800795 and rs1800796 IL6 polymorphisms and CRC. We evaluated the joint effects of IL6 single nucleotide polymorphisms and regular use of aspirin/NSAIDs and vitamin D receptor (VDR) genotype. Having a C allele of the rs1800796 IL6 polymorphisms and the GG genotype of the rs1800795 IL6 polymorphisms was associated with a statistically significantly reduced the risk of colon (OR 0.76 95% CI 0.57, 1.00), but not rectal (OR 1.49 95% CI 1.02,2.16) cancer. Both IL6 polymorphisms were associated with significant interaction with current use of aspirin/NSAIDs to alter risk of colon cancer: individuals with a C allele in either polymorphism who were current users of aspirin/NSAIDs had the lowest colon cancer risk. CRC risk also was associated with an interaction between VDR and IL6 genotypes that was modified by current use of aspirin/NSAIDs. This study provides further support for inflammation-related factors in the etiology of CRC. Other studies are needed to explore other genes in this and other inflammation-related pathways.

show abstract

“…It is now well established that patients with ulcerative colitis have an increased risk of developing carcinoma of the colon (Rosenqvist, Ohrling, Lagercrantz, and Edling, 1959;Edwards and Truelove, 1964;Goldgraber and Kirsner, 1964).…”

mentioning

confidence: 99%

In-situ and invasive carcinoma of the colon in patients with ulcerative colitis

Evans¹,

Pollock²

1972

Gut

View full text Add to dashboard Cite

SUMMARY Four cases are described in which ulcerative colitis was complicated by carcinoma and in which the extent of the accompanying in-situ carcinoma (precancer) was determined.The extent of the in-situ carcinoma was very variable and in all cases the rectum was spared in whole or part. Search for in-situ carcinoma in rectal biopsies will fail to indicate the development of malignancy in some patients with ulcerative colitis. Alternative methods of cancer detection in this group are discussed.

show abstract

Carcinoma of the colon in ulcerative colitis

Cited by 110 publications

References 31 publications

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

IL6 genotypes and colon and rectal cancer

In-situ and invasive carcinoma of the colon in patients with ulcerative colitis

Contact Info

Product

Resources

About